51 results on '"Lee, Scott A."'
Search Results
2. Characterizing Hospitalization Trajectories in the High-Need, High-Cost Population using Electronic Health Record Data
3. The impact of thiamethoxam on the feeding and behavior of 2 soybean herbivore feeding guilds
4. A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index
5. Can treatment support mitigate nicotine metabolism-based disparities in smoking abstinence? Secondary analysis of the Helping HAND 4 trial
6. A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
7. SAFETY AND EFFICACY OF MYCOPHENOLATE MOFETIL TREATMENT FOR REFRACTORY CROHN'S DISEASE
8. THE RELATIONSHIP BETWEEN SELF-REPORTED SLEEP, WRIST ACTIGRAPHY, AND SYMPTOMS AMONG ADULTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
9. Performance of Existing and Novel Symptom- and Antigen Testing–Based COVID-19 Case Definitions in a Community Setting
10. Deep Remission in Severe Refractory Crohn’s Disease With Mycophenolate Mofetil
11. Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
12. Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
13. RELATIONSHIP BETWEEN SELF-REPORTED SLEEP AND DISEASE ACTIVITY DIFFERS BASED ON ENDOSCOPIC OR CLINICAL DISEASE ACTIVITY MEASURES
14. CORRELATION OF FECAL, PLASMA, SERUM, AND SALIVARY CALPROTECTIN TO ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN PATIENTS WITH CROHN’S DISEASE
15. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
16. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
17. Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn’s Disease
18. Patient with Fistulizing Crohn’s Disease with Nonresponse to Infliximab Subsequently Responds to Infliximab After Short-term Addition of Tacrolimus
19. Synergisms in Science: Climate Change and Integrated Pest Management Through the Lens of Communication—2019 Student Debates
20. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
21. P068 MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
22. P042 FATIGUE AND DISEASE ACTIVITY: A SECONDARY REVIEW OF PATIENT MEDICAL RECORDS
23. P089 REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE
24. P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY
25. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
26. P142 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL TO EVALUATE INDUCTION OF CLINICAL RESPONSE IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE TREATED WITH RIFAXIMIN
27. P136 CERTOLIZUMAB PEGOL IS EFFECTIVE IN THE MAINTENANCE OF RESPONSE IN MODERATE-SEVERE ULCERATIVE COLITIS: AN OPEN-LABEL MAINTENANCE STUDY
28. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol
29. Reply
30. Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease
31. Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Experiencing Disease Exacerbation
32. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα
33. P-101 Incidence of Anti-drug Antibodies in Crohnʼs Disease Patients During 5 Years of Certolizumab Pegol Therapy
34. P-104 SECURE
35. P-099 Current Smoking Status Is a Risk Factor For Loss of Remission in Crohnʼs Disease Patients Treated with Certolizumab Pegol
36. P-095 A Pooled Analysis of Malignant Events with a Focus on Lymphoma from 15 Crohnʼs Disease Studies with Certolizumab Pegol
37. P-105 Dermatologic Complications in Patients Treated with Certolizumab Pegol
38. Briakinumab for Treatment of Crohnʼs Disease
39. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series
40. Utilization of Baclofen in Maintenance of Alcohol Abstinence in Patients with Alcohol Dependence and Alcoholic Hepatitis with or without Cirrhosis
41. Genotype, development and tissue-derived variation of cell-wall properties in the lignocellulosic energy crop Miscanthus
42. P-100 Anti-Drug Antibodies Separate Responses of Markers of Inflammation (C-Reactive Protein, Fecal Calprotectin) in Crohnʼs Disease Patients Treated with Certolizumab Pegol
43. P-085 Evaluation of Switch in Rescue Agents
44. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines
45. Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial
46. The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECiSE 2 Trial
47. The association of psoriasis with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A AQ1 single-center case series
48. Baseline C-reactive protein (CRP) and plasma anti-TNF concentration in patients with active Crohnʼs disease treated with certolizumab pegol
49. Long-term therapy with sargramostim in a patient with Crohnʼs disease
50. Prevalence of and risk factors for vitamin B12 deficiency in patients with Crohnʼs disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.